These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27683035)

  • 1. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
    Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
    Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
    Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
    Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
    Bernell P; Jacobsson B; Nordgren A; Hast R
    Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage.
    van Lom K; Hagemeijer A; Smit E; Hählen K; Groeneveld K; Löwenberg B
    Leukemia; 1995 Nov; 9(11):1818-21. PubMed ID: 7475268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
    Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
    Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.
    Mehrotra B; George TI; Kavanau K; Avet-Loiseau H; Moore D; Willman CL; Slovak ML; Atwater S; Head DR; Pallavicini MG
    Blood; 1995 Aug; 86(3):1139-47. PubMed ID: 7542497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
    Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
    Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency.
    Qi H; Qingxia Z; Xiao L; Lingyun W; Feng X; Zheng Z; Chunkang C
    Cancer Invest; 2015; 33(8):369-77. PubMed ID: 26135215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study.
    Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
    J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
    Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
    Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
    Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
    Knorr KL; Finn LE; Smith BD; Hess AD; Foran JM; Karp JE; Kaufmann SH
    Stem Cells Transl Med; 2017 Mar; 6(3):840-850. PubMed ID: 28297583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
    Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
    Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
    Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic evidence for involvement of erythroid progenitors in a child with therapy linked myelodysplasia.
    Grier HE; Weinstein HJ; Révész T; Houlihan PW; Greenhalgh CL; Nathan DG; Tantravahi R
    Br J Haematol; 1986 Nov; 64(3):513-9. PubMed ID: 3466643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome without evidence of myelodysplastic syndrome or acute myelogenous leukemia.
    Sokolic RA; Ferguson W; Mark HF
    Cancer Genet Cytogenet; 1999 Dec; 115(2):106-13. PubMed ID: 10598142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.